NHS: Drugs

(asked on 29th January 2018) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the Office of Health Economics' Report, Routine Funding in the NHS in the UK of Medicines Authorised Between 2011 and 2016 via the European Centralised Procedure, published in December 2017.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 6th February 2018

Any robust analysis of medicines use in the United Kingdom will be taken into account in the development of future medicines policy. The Government wants patients to be able to benefit from clinically and cost effective new drugs as soon as possible.

On 3 November, the Government published its response to the Accelerated Access Review. It set out plans to give patients quicker access to life-changing treatments; and, make the UK the best place in the world for industry to invest and innovate. From April 2018, the new Accelerated Access Pathway will mean selected products with the greatest potential to change lives could be available up to four years earlier by reducing the time taken to negotiate the evaluation and financial approvals necessary before the National Health Service can purchase them.

Reticulating Splines